Generex Biotechnology Corporat... ( GNBT )

Rate Stock
Overperform
Underperform
Sentiment:
0.00 /100
Last Price:
0.0311
Change:
-19.43%
Key Indicators
Prev. Close 0.0386
Day Range 0.03 - 0.043
52wk Range 0.025 - 0.044
Volume 15,872,813
Avg Vol. 2,189,211
Shares Outs. 490,001,537
Market Cap 15,239,048
P/E N/A
EPS -0.02
Dividend/Yield None / 0.00%
Stock Wall - GNBTLatest News - GNBT
Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine
Generex Comments on Results of Stockholders` Meeting
GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
GENEREX BIOTECHNOLOGY CORP Financials
GENEREX BIOTECHNOLOGY CORP Files SEC form 10-Q, Quarterly Report
Generex Touts Pipeline Potential of Antigen Express Subsidiary
Generex Biotechnology Corporation's CEO Discusses Investor Conference Call Transcript
GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Generex Points to Potential of Antigen Express Technology Platform beyond Its AE37 Breast Cancer Vaccine
Generex: Research For Sale On The Cheap
GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Generex Provides an Overview of its Cancer Immunotherapy Product, AE37, and Potential in Early Breast Cancer Given Current and Potential Future Therapies
GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Change in Directors or Principal Officers
GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Unregistered Sale of Equity Securities, Amendments to Articles of Inc.
GENEREX BIOTECHNOLOGY CORP Files SEC form 10-Q, Quarterly Report
GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Of
GENEREX BIOTECHNOLOGY CORP Files SEC form 10-K, Annual Report
GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Unregistered Sale of Equity Securities, Amendments to Articles of Inc.
GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
1 new update